Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188
  • Algernon is completing the intravenous formulation that will be used in the study and has retained the Centre for Human Drug Research in the Netherlands
  • The company is planning to begin the Phase 1 study in September
  • Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share

Algernon (AGN) has provided an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”).

The company is currently working to complete the intravenous formulation that will be used in the Phase 1 DMT study and has retained the Centre for Human Drug Research and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands, to complete the work.

Algernon plans to begin the Phase 1 study in September of 2022.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the news.

The primary focus of Algernon’s planned Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT. The resulting data will help the company plan its Phase 2 acute stroke and rehabilitation studies.

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug that produces effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.42 per share.

More From The Market Herald

" Miners highlight the role of commodities in your portfolio

As supply chain constraints linger across the globe, prospective commodity allocations are front and centre.

" @ the Bell: Markets retreat at the end of the week

Canada’s main stock index posted a triple digit decline by Friday’s close thanks to losses in the technology and base metal sectors.
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.